Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.

Name: Αlpha¹ Rigor Record — Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.
Item: Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.
Rating: 100
Author: Αlpha¹

Zhang Y, Li J, Wang M, Li X, Yan B, Liu J, Shi L, Cao Z, Feng Y, Liu W, Xu Z, Ma R, Gao X, Liu W, Xue J, Ren X, Li X, Song X, Yang Y, Wang Y, Xing Z, Quan F, Pan J, Sun Y, Shi F, Chen X, Yan H, Zhao G, Chen B, Wang C, Zhang L

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 1 high issue for “Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 30 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3 randomized controlled trial. The design is rigorous with proper randomization, blinding, power analysis, and pre-specified endpoints. All eight rigor dimensions pass, with minor copyedit issues and one unresolved reference flagged.

Both reviewers independently scored all eight dimensions as 'pass' with high confidence, and their evidence was consistent. The study type is interventional (phase 3 RCT). The statistics verification recomputed 6 tests consistently, but coverage is limited to tests with test statistics/df or effect estimates with CIs; threshold-only p-values and resampling-based p-values were not machine-verified. The citation check flagged one reference (the Zenodo code DOI) as not found in the registry, which is a data/code link rather than a citation to prior literature.

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 6 tests: 6 consistent, 0 inconsistent; 6 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites multiple prior studies and meta-analyses on omalizumab and anti-IL-4/IL-4Rα biologics, acknowledges their limitations (cost, lack of seasonal add-on trials), and identifies a gap. The rationale for stapokibart and the specific patient population (eosinophil ≥300) is derived from the phase 2 MERAK trial. Limitations of prior work are addressed by designing a trial during natural pollen exposure.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on SAR burden, limitations of current treatments, and prior biologics trials, and logically links this to the study's objectives.

Evidence

direct quote[Main, paragraphs 1-3]

“Previous RCT trials as well as meta-analysis studies have shown the significant efficacy of pre- and co-seasonal administration of omalizumab (an anti-IgE monoclonal antibody) in improving nasal and ocular symptoms, and QOL in patients with SAR during the pollen season”